Précis: More extensive biopsy protocol improved prostate cancer detection rate
Transrectal ultrasound (TRUS) and TRUS-guided biopsy have become the method of choice for the detection of prostate cancer, especially when curative treatment is planned. In the recent years, a sis biopsy (sextant) protocol has been used by many centers. However, the sextant method may underestimate the presence of cancer. In this study, the researchers evaluated more extensive biopsy protocol in an attempt to improve the detection rate.
A total of 303 patients underwent TRUS-guided biopsy of prostate gland because of elevated prostate-specific antigen (PSA) levels or an abnormal digital rectal examination. At least 10 biopsies were obtained for each patient, including sextant biopsies.
The more extensive biopsy protocol improved the detection rate by 6.6% to 38.9% compared with standard sextant biopsies.
The complication rate was 1%.
In this study, adding peripheral cores to the standard sextant needle biopsies of the prostate significantly improves the cancer detection rate. More extensive biopsy appeared to be well tolerated. The optimal number of samples to be taken and the clinical importance of isoechoic cancer seen on ultrasound have yet to be defined. This study did provide some rational arguments for the decision on an optimal protocol.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.